# First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

> **NCT02906163** · PHASE1,PHASE2 · UNKNOWN · sponsor: **SciClone Pharmaceuticals** · enrollment: 188 (estimated)

## Conditions studied

- EGFR Mutation Positive Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Thymalfasin (Thymosin alpha 1, Ta1)
- **DRUG:** SoC (tyrosine kinase inhibitor)

## Key facts

- **NCT ID:** NCT02906163
- **Lead sponsor:** SciClone Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-10
- **Primary completion:** 2019-12
- **Final completion:** 2020-01
- **Target enrollment:** 188 (ESTIMATED)
- **Last updated:** 2016-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02906163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02906163, "First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT02906163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*